(NASDAQ: NRXP) Nrx Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.06%.
Nrx Pharmaceuticals's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast NRXP's revenue for 2024 to be $64,118,853, with the lowest NRXP revenue forecast at $64,118,853, and the highest NRXP revenue forecast at $64,118,853. On average, 1 Wall Street analysts forecast NRXP's revenue for 2026 to be $478,498,900, with the lowest NRXP revenue forecast at $478,498,900, and the highest NRXP revenue forecast at $478,498,900.
In 2027, NRXP is forecast to generate $1,913,995,600 in revenue, with the lowest revenue forecast at $1,913,995,600 and the highest revenue forecast at $1,913,995,600.